AIM: The aim of this study was to evaluate the prevalence of erectile dysfunction (ED) in a sample of type 2 diabetic patients.
As secondary endpoint, we evaluated the levels of some adipocytokines in patients with and without ED.
MATERIAL AND METHODS: We enrolled 220 males affected by type 2 diabetes mellitus. We administered the IIEF (International Index of Erectile Function), SAS (self-rating anxiety scale) and SDS (self-rating depression scale) questionnaires. We evaluated body mass index, glycemic control, fasting plasma insulin (FPI), homeostasis model assessment of insulin resistance index (HOMA-IR), lipid profile, sexual hormones, adiponectin (ADN), resistin, retinol binding protein-4 (RBP-4), visfatin, vaspin.
RESULTS: 52.9% of patients were affected by ED. Patients with a HbA1c < 7% (53mmol/mol) in all measurements in the two previous years had a lower incidence of ED, while the prevalence of ED increased with the increasing of times HbA1c was >7% (53mmol/mol). Patients with ED had higher levels of triglycerides, and higher levels of FPI, 9.9μU/ml vs 8.2μU/ml (p< 0.05). Resistin levels were higher in patients with ED compared to those without ED (p< 0.05) and free testosterone was lower in patients affected by ED.
CONCLUSIONS: Almost half of type 2 diabetic patients attending our clinic were affected by ED and glycemic control seems to play a role in ED pathogenesis.
Written by:
Derosa G, Romano D, Tinelli C, D'Angelo A, Maffioli P. Are you the author?
Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, Pavia, Italy; Biometric Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; PhD School in Experimental Medicine, University of Pavia, Pavia, Italy.
Reference: Diabetes Res Clin Pract. 2015 Feb 7. pii: S0168-8227(15)00077-7.
doi: 10.1016/j.diabres.2015.01.037
PubMed Abstract
PMID: 25747572